Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect the skin, joints, kidneys, brain and other organs. Approximately 200,000 cases are diagnosed each year. The of Lupus remain unknown, but both environmental and genetic factors are likely to contribute.
MMRI researchers are studying the effects of elevated protein activity in patients with lupus. We believe that an increased protein activity of one particular enzyme called SHP2 may cause increase Lupus progression and associated organ damage.
The Kontaridis Lab at MMRI is focusing on SLE research.
One aim of there research is to develop targeted drugs for the treatment of SLE. The MMRI hopes to create a drug that targets disease onset preventing lupus pathology.
“My own mother’s 26-yearlong battle with lupus motivated me and inspired this investigation. Our findings and others like this, give great hope that one day soon there will be newer and better treatment options available for the millions of patients that suffer with this disease.”
-Maria Kontaridis, Director of Research